Literature DB >> 9203649

Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgG.

G H Lowell1, R W Kaminski, T C VanCott, B Slike, K Kersey, E Zawoznik, L Loomis-Price, G Smith, R R Redfield, S Amselem, D L Birx.   

Abstract

Intranasal immunization of mice with human immunodeficiency virus (HIV) rgp160 complexed to proteosomes improved anti-gp160 serum IgA and IgG titers, increased the number of gp160 peptides recognized, and stimulated anti-gp160 intestinal IgA compared with immunization with uncomplexed rgp160 in saline. These enhanced responses were especially evident when either a bioadhesive nanoemulsion (emulsomes) or cholera toxin B subunit (CTB) was added to the proteosome-rgp160 vaccine. Furthermore, anti-gp160 IgG and IgA in vaginal secretions and fecal extracts were induced after intranasal immunization with proteosome-rgp160 delivered either in saline or with emulsomes. Formulation of uncomplexed rgp160 with emulsomes or CTB also enhanced serum and selected mucosal IgA responses. Induction of serum, vaginal, bronchial, intestinal, and fecal IgA and IgG by intranasal proteosome-rgp160 vaccines delivered in saline or with emulsomes or CTB is encouraging for mucosal vaccine development to help control the spread of HIV transmission and AIDS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203649     DOI: 10.1093/infdis/175.2.292

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Mucosal anti-CD3 monoclonal antibody attenuates collagen-induced arthritis that is associated with induction of LAP+ regulatory T cells and is enhanced by administration of an emulsome-based Th2-skewing adjuvant.

Authors:  Henry Yim Wu; Ruth Maron; Ann-Marcia Tukpah; Howard L Weiner
Journal:  J Immunol       Date:  2010-08-18       Impact factor: 5.422

2.  Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.

Authors:  Soumi Gupta; Ramesh Janani; Qian Bin; Paul Luciw; Catherine Greer; Silvia Perri; Harold Legg; John Donnelly; Susan Barnett; Derek O'Hagan; John M Polo; Michael Vajdy
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

3.  Mucosal adjuvant properties of the Shigella invasin complex.

Authors:  Robert W Kaminski; K Ross Turbyfill; Edwin V Oaks
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.

Authors:  L F Fries; A D Montemarano; C P Mallett; D N Taylor; T L Hale; G H Lowell
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

5.  Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae.

Authors:  L Goetsch; A Gonzalez; H Plotnicky-Gilquin; J F Haeuw; J P Aubry; A Beck; J Y Bonnefoy; N Corvaïa
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

6.  Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses.

Authors:  Kristina Abel; Lara Compton; Tracy Rourke; David Montefiori; Ding Lu; Kristina Rothaeusler; Linda Fritts; Kristen Bost; Christopher J Miller
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins.

Authors:  Diana I Albu; Agnes Jones-Trower; Amy M Woron; Kathleen Stellrecht; Christopher C Broder; Dennis W Metzger
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

8.  Nasal vaccination with troponin reduces troponin specific T-cell responses and improves heart function in myocardial ischemia-reperfusion injury.

Authors:  Dan Frenkel; Alok S Pachori; Lunan Zhang; Adi Dembinsky-Vaknin; Dorit Farfara; Sanja Petrovic-Stojkovic; Victor J Dzau; Howard L Weiner
Journal:  Int Immunol       Date:  2009-06-10       Impact factor: 4.823

9.  Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids.

Authors:  C C Bowman; J D Clements
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

10.  Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55.

Authors:  J A Neidleman; M Vajdy; M Ugozzoli; G Ott; D O'Hagan
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.